• image
  • image
  • image
 

AIDS Vaccine 2010

at the Omni Hotel at CNN Center

Scientific Program Overview
The full program can be accessed here.

Jump to sessions: Tuesday   |   Wednesday  |   Thursday   |   Friday


Tuesday, 28 September, 2010


Opening Session
PDF Abstracts


16:30 - 16:35       Eric Hunter
Emory University
Atlanta, Georgia, USA

16:35 - 16:40       Alan Bernstein
Global HIV Vaccine Enterprise
New York, New York, USA

16:40 - 17:00       Thomas Frieden
Centers for Disease Control
Atlanta, Georgia, USA
PDF Slides

17:00 - 17:10       Kathleen Sebelius
United States Department of Health and Human Services
Washington, DC, USA

17:10 - 17:25       The Atlanta Gay Men's Chorus

17:25 - 17:40       Dazon Dixon Diallo
Sisterlove Inc.
Atlanta, Georgia, USA

17:40 - 17:55       Malegapuru William Makgoba
University of KwaZulu-Natal
KwaZulu-Natal, South Africa

17:55 - 18:30       The Path to an HIV Vaccine: Follow the Science
Anthony Fauci
National Institute of Allergy and Infectious Disease, National Institutes of Health
Bethesda, Maryland, USA


Wednesday, 29 September, 2010


Plenary Session 01: Improving Immunogens and Delivery
PDF Abstracts

08:00 - 08:05       Welcome Remarks

James Wagner

President of Emory University
Atlanta, Georgia, USA


08:05 - 08:35       Clues from the Isolation and Structural Analysis of Broadly

Neutralizing Anti-HIV-1 Antibodies
John Mascola

Vaccine Research Center, NIAID, NIH
Bethesda, Maryland, USA


08:35 - 09:05       Designing Vaccine Inserts with Enhanced

Potential to Contend with HIV Diversity
Bette Korber

Theoretical Biology, Los Alamos National Laboratory
Los Alamos, New Mexico, USA
PDF Slides


09:05 - 09:35       Virus Vectors in the Iterative Process of HIV

Vaccine Development: What Is Next?
Giuseppe Pantaleo

Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland


Oral Abstract Session 01: Novel Immunogens & Inserts
PDF Abstracts

10:00 - 10:15       A Global AIDS Vaccine Based on Conserved Elements

of the Viral Proteome
James Mullins

University of Washington
Seattle, Washington USA
PDF Slides


10:15 - 10:30       Codon Optimization of HIV-1 Vaccines Decreases

the Potential Breadth of CD8+ T-Cell Responses
Anne Bet

University of Alabama at Birmingham
Birmingham, Alabama, USA


10:30 - 10:45       Co-delivery of Mucosal Chemokine Plasmids in

Systemically Administered DNA Vaccines Elicits Systemic
and Mucosal Immune Responses in Rhesus Macaques

Michele Kutzler

Drexel University College of Medicine
Philadelphia, Pennsylvania, USA


10:45 - 11:00       Control of Pathogenic SIVmac239 Following

Electroporated DNA + IL-12 Prime and Adenovirus
5 Boost in the NHP mode

Adrian McDermott

International AIDS Vaccine Initiative (IAVI)
Brooklyn, New York, USA
PDF Slides


11:00 - 11:15       Prevention of Systemic Infection by a Multigenic

Recombinant Protein Vaccine after Heterologous
R5 Clade C SHIV Challenge: Correlates of Protection

Robert Rasmussen

Dana-Farber Cancer Institute
Boston, Massachusetts, USA
PDF Slides


11:15 - 11:30       Sustainable High Titer Neutralizing Antibodies are

Rapidly Induced by Novel Virus-Like Particles
when Combined with DNA Vaccines in Rabbits

Shelly Krebs

Oregon Health and Sciences University
Beaverton, Oregon, USA
PDF Slides


11:30 - 11:45       Indicators of Therapeutic Vaccine Effect Using

GTU®-MultiHIV B clade DNA in Treatment-naïve
Subtype C HIV-1 Infected Subjects

Eftyhia Vardas

University of Stellenbosch
Johannesburg, South Africa
PDF Slides


11:45 - 12:00       Improved Immunogenicity Against HIV-1 Clade C

Antigens by Using NYVAC-C with Restored Replication Competence
Petra Mooij

Biomedical Primate Research Centre
Rijswijk, Netherlands
PDF Slides



Oral Abstract Session 02: T-cell Immunity and Immune Escape
PDF Abstracts

10:00 - 10:15       CTL Escape and Reversion in HIV-1 Gag, Pol and

Nef in an African Subtype C Cohort
Malinda Schaeferm

Emory University
Atlanta, Georgia, USA
PDF Slides


10:15 - 10:30       High Magnitude and Multifunctionality Epitope-

specific CD8+ T-cell Responses are Associated
with Selection of Escape Mutants in Acute HIV Infection

Guido Ferrari

Duke University Medical Center
Durham, North Carolina, USA
PDF Slides


10:30 - 10:45       Escape from Neutralization is a Frequent Event in

HIV-2 Infection and is Strongly Associated with X4 Tropism
José Maria Marcelino

Instituto de Higiene e Medicina Tropical
Lisboa, Portugal
PDF Slides


10:45 - 11:00       Modulation of Cytolytic Activity of CD8+ T cells by

HIV-1-specific IL21+ CD4+ T cells
Hendrik Streeck

Ragon Institute of MGH, MIT and Harvard
Charlestown, Massachusetts, USA


11:00 - 11:15       A Potential Role for T-bet in Eliciting the Increased

Cytotoxic Potential Demonstrated by HIV-specific
CD8+ T-cells in HIV Elite Controllers

Adam R. Hersperger

University of Pennsylvania
Philadelphia, Pennsylvania, USA
PDF Slides


11:15 - 11:30       Dominant Clonotypes Within HIV-specific T cell

Responses Display an Exhaustion Phenotype and
Reduced Epitope Cross-Reactivity

Joseph Conrad

Vanderbilt University
Nashville, Tennessee, USA
PDF Slides


11:30 - 11:45       Modulation of TCR Avidity of Primary HIV-1-

Specific CD8 T-cell Responses by Early and
Potent Antiviral Therapy Responses

Alexandre Harari

Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland


11:45 - 12:00       The Glycan Shield of HIV-1 is Composed of an

Extended, Non-self Carbohydrate Array that is
Highly Conserved Between Geographically
Divergent Clades

Chris Scanlande

Oxford University, Glycobiology Institute
Oxford, United Kingdom
PDF Slides



Oral Abstract Session 03: Results & Insights from Advanced Clinical Trials
PDF Abstracts

10:00 - 10:15       Psychosocial Consequences of Participation in

HIV Preventive Vaccine Trials: a Cross-sectional Study in
ANRS COV1-COHVAC Cohort

Christine Durier

INSERM SC10
Villejuif, France
PDF Slides


10:15 - 10:30       "Speaking the Dialect": Understanding Public

Discourse in the Aftermath of an Early HIV
Vaccine Trial Termination

Peter A. Newman

University of Toronto
Toronto, Ontario, Canada
PDF Slides


10:30 - 10:45       False HIV Seropositive Among Uninfected HIV

Vaccine Recipients of Phase III Vaccine Trial in Thailand
Sutchana Tabprasit

Armed Forces Research Institute of Medical Science (AFRIMS)
Bangkok, Thailand
PDF Slides


10:45 - 11:00       Exploratory Age-stratified Analysis of Risk-taking

Behaviors and Trial Participation Outcomes in the
Thai Phase III HIV Vaccine Trial

Punnee Pitisuttithum

Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand
PDF Slides


11:00 - 11:15       Analysis of the Relative Risk of HIV Acquisition

Among Step Study Participants with Extended Follow-up
Ann Duerr

HIV Vaccine Trials Network
Seattle, Washington, USA


11:15 - 11:30       Optimal Priming of Poxvirus Vector (NYVAC)-

Based HIV Vaccine Regimens Requires 3 DNA
Rnjections. Results of the EV03/ANRS Vac20 Phase I/II Trial

Yves Levy

Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Vaud, Switzerland
PDF Slides


11:30 - 11:45       Broad and Strong Immune Responses in a Trial of

a Heterologous DNA Prime MVA Boost HIV
Vaccine among Healthy Tanzanian Volunteers

Said Aboud

Muhimbili University of Health and Allied Sciences
Dar es Salaam, United Republic of Tanzania
PDF Slides


11:45 - 12:00       Vaccine-induced Seropositivity (VISP) Following

Immunization of Healthy Individuals with HIV DNA
and Recombinant Modified Vaccinia Virus Ankara

Andreas Bråve

Swedish Institute for Infectious Disease Control and Karolinska Institute
Solna, Sweden
PDF Slides



Oral Abstract Session 04: Acute Infection/Viral Diversity
PDF Abstracts


13:00 - 13:15       HIV-1 Acute Infection: Evidence of Selection?

Morgane Rolland, NIA Winner

University of Washington
Seattle, Washington, USA
PDF Slides


13:15 - 13:30       Molecular Targets and Potency of HIV-1

Neutralization Revealed by Dynamic Assessment of
Transmitted/Founder Virus Antibody
Recognition and Escape

Katharine Bar

University of Alabama at Birmingham
Birmingham, Alabama, USA
PDF Slides


13:30 - 13:45       Early Appearance of ADCC- and ADCVI-Mediating

Antibody Responses Against Autologous HIV-1
Transmitted/Founder Virus

Guido Ferrari

Duke University Medical Center
Durham, North Carolina, USA
PDF Slides


13:45 - 14:00       Ligand Dependant Increase in KIR Gene

Expression in Primary HIV-1 Infection
Ramona Moodley

University of KwaZulu Natal
Durban, KwaZulu Natal, South Africa
PDF Slides


14:00 - 14:15       Decrease in the Ratio of Infectious to Total Virions

During Acute HIV-1 Infection
Genevieve Fouda

Duke University Medical Center
Durham, North Carolina, USA
PDF Slides


14:15 - 14:30       Evolution of HIV-1 Diversity in Regions of High

Viral Diversity and Implications for Vaccine design
Luzia Mayr

New York University School of Medicine and VA Medical Center
New York, New York, USA
PDF Slides



Oral Abstract Session 05: Novel Monoclonals and Structural Insights
PDF Abstracts


13:00 - 13:15       Structural insights into HIV-1 Neutralization by

Broadly Neutralizing Antibodies PG9 and PG16
Ian Wilson

The Scripps Research Institute
La Jolla, California, USA
PDF Slides


13:15 - 13:30       Crystal Structure of the Neutralizing Antibody

HK20 in Complex with its gp41 Antigen
David Lutje Hulsik

Unit of Virus Host Cell Interactions (UVHCI)
Grenoble, France
PDF Slides


13:30 - 13:45       Role of Complex Carbohydrates in Human

Immunodeficiency Virus Type 1 Infection and
Resistance to Antibody Neutralization

James Binley

Torrey Pines Institute
San Diego, California, USA
PDF Slides


13:45 - 14:00       New Broadly Neutralizing Human Monoclonal

Antibodies Targeting the 2F5 Epitope
Zhongyu Zhu

NCI Frederick NIH
Frederick, Maryland, USA


14:00 - 14:15       Isolation of Human Monoclonal Antibodies from

HIV-Uninfected Subjects Immunized with
gp120/NefTat/AS01B by Dual-Color Antigen-
Specific B Cell Sorting

M. Anthony Moody

Duke University Medical Center
Durham, North Carolina, USA
PDF Slides


14:15 - 14:30       Affinity Maturation allows VRC01-like Antibodies

to Converge on a Common Mode of Effective HIV-1
Neutralization

Peter Kwong

Vaccine Research Center, NIADI/NIH
Bethesda, Maryland, USA
PDF Slides



Oral Abstract Session 06: Pre-Clincal & Early Clinical Trials
PDF Abstracts

13:00 - 13:15       HIV-1 envelope-CD4 Receptor Complexes Elicit

Broad T- and B-cell Immune Responses as well as
Cross-Reactive Neutralizing Antibodies in
Rhesus Macaques

Willy Bogers

Biomedical Primate Research Centre
Rijswijk, Netherlands
PDF Slides


13:15 - 13:30       CD40L Expressed on Virus-like Particles

Adjuvants Prevention of Acquisition Mediated by a
DNA/MVA Vaccine

Rama Rao Amara

Emory University
Atlanta, Georgia, USA


13:30 - 13:45       Enhanced Magnitude of Immune Responses

Induced by SIV Antigens Delivered by Plasmid
DNA via Electroporation and Boosted by
Recombinant Adenovirus 5

David Weiner

University of Pennsylvania
Philadelphia, Pennsylvania, USA
PDF Slides


13:45 - 14:00       Preliminary Results of Safety and Immunogenicity

of Ad35-GRIN/Env HIV Vaccine in HIV-uninfected Subjects
(IAVI B001)

Michael Keefer

International AIDS Vaccine Initiative (IAVI)
New York, New York, USA
PDF Slides


14:00 - 14:15       Immunogenicity of ALVAC-HIV vCP1521 in Infants

Born to HIV-1 Infected Women in Uganda (HPTN 027)
Huyen Cao

California Department of Public Health
Richmond, California, USA


14:15 - 14:30       Safety and Immunogenicity of DNA Prime and

Modified Vaccinia Ankara Virus HIV Subtype
Cboost in Indian Volunteers

Vadakkuppattu Ramanathan

Tuberculosis Research Centre
Chennai, India



Special Session: The Launch of the Global HIV Vaccine Enterprise 2010 Scientific Strategic Plan for HIV Vaccine Development

14:30 - 14:35       Opening Remarks

Alan Bernstein

Global HIV Vaccine Enterprise
New York, New York, USA
PDF Slides


14:35 - 15:15       Panel Presentations

Margaret Johnston

NIH/NIAID
USA
PDF Slides

Catherine Hankins

UNAIDS
Geneva, Switzerland
PDF Slides

Seth Berkley

International AIDS Vaccine Initiative
New York, New York, USA
PDF Slides

Glenda Gray

HIV Vaccine Trials Network
Johannesburg, South Africa
PDF Slides

Jose Esparza

The Bill and Melinda Gates Foundation
Seattle, Washington, USA


15:15 - 16:00       Moderated Panel Discussion and Closing Remarks
Alan Bernstein
Global HIV Vaccine Enterprise
New York, New York, USA


Symposium 01: Novel Immunogen, Adjuvant and Vaccine Delivery Strategies
PDF Abstracts

16:00 - 16:25       Immunogen Designs to Elicit Broadly Neutralizing

Antibodies: Introduction to the Problem and
Approaches for Induction Using New Reagents

Richard Wyatt

IAVI Neutralizing Antibody Center, The Scripps Research Institute
La Jolla, California, USA


16:25 - 16:50       Design of Novel CD4-binding Site Antigens

William Schief

University of Washington
Seattle, Washington, USA


16:50 - 17:15       Immunogen Designs to Elicit Broad and Robust

Cell Mediated Immune Responses: Introduction to
the Problem: Antigenic Inserts for Inclusion in
HIV Vaccines

Tomas Hanke

University of Oxford
Oxford, United Kingdom
PDF Slides


17:15 - 17:40       Adjuvants for Induction of Cell Mediated Immune

Responses
Nathalie Garcon

GlaxoSmithKline Biologicals
Wavre, Belgium



Symposium 02: Early Phase Clinical Trials
PDF Abstracts

16:00 - 16:25       DNA Vector/Electroporation Immunogenicity Trials

Sandhya Vasan

Aaron Diamond AIDS Research Center and the Rockefeller University
New York, New York, USA


16:25 - 16:50       DNA/Vaccinia Prime Boost Immunogenicity Trials

Eric Sandstrom

Karolinska Institutet
Stockholm, Sweden
PDF Slides


16:50 - 17:15       The Safety and Immunogenicity of HIV-1 Vaccines
Based on DNA and Replication Competent
Vaccinia Vector in Phase I Clinical Trial

Yiming Shao
National Center for AIDS/STD Control and Prevention,
Chinese Center for Disease Control and Prevention
Beijing, China
PDF Slides

17:15 - 17:40       Alternative Serotype Adenovirus Vectors

Dan Barouch

Beth Israel Deaconess Medical Center
Boston, Massachusetts, USA
PDF Slides



Symposium 03: Animal Models of HIV Transmission
PDF Abstracts

16:00 - 16:25       Challenge Challenges: Considerations in the use

of Non-Human Primate Models for Studies of AIDS
Virus Transmission and Vaccine Evaluation
Jeffery Lifson

AIDS and Cancer Virus Program,
SAIC Frederick, Inc., National Cancer Institute
Frederick, Maryland, USA
PDF Slides


16:25 - 16:50       Persistent Vectors and Early Control of Highly
Pathogenic SIV
Louis Picker
Vaccine & Gene Therapy Institute, Oregon Health & Science University,
Oregon National Primate Research Center
Beaverton, Oregon, USA

16:50 - 17:15       Immune Correlates of Protection

David Watkins

University of Wisconsin-Madison
Madison, Wisconsin, USA
PDF Slides


17:15 - 17:40       The impact of TRIM5 Polymorphism on Viremia in

Rhesus Macaques
Vanessa Hirsch

NIH, NIAID, LMM
Bethesda, Maryland, USA
PDF Slides



Thursday, 30 September, 2010

Plenary Session 02: Lessons from Host-Virus Interactions
PDF Abstracts
08:30 - 09:00       Innate-Mucosal Immune Interactions During Acute Infection

Ashley Haase

Department of Microbiology, University of Minnesota Medical School
Minneapolis, Minnesota, USA


09:00 - 09:30       Lessons from Early HIV Infection

Andrew McMichael

University of Oxford
Oxford, Oxfordshire, United Kingdom


09:30 - 10:00       HIV Transmission and the Role of Antibodies:

Lessons from the Settings of Mother-Infant
Infection and Superinfection

Julie Overbaugh

Fred Hutchinson Cancer Research Center
Seattle, Washington, USA
PDF Slides



Oral Abstract Session 07: Prevention Strategies
PDF Abstracts

10:30 - 10:45       Preventive HIV Vaccine Acceptability and

Behavioral Risk Compensation Among Men who
have Sex with Men in Nigeria, Sub-Saharan Africa

Olusegun Busari

Federal Medical Centre
Ido-Ekiti, Nigeria


10:45 - 11:00       Mucosal SHIV Exposures and Oral PrEP Can

Induce Specific T cell Responses, and Can have a
Chemo-Vaccination Effect

Ellen Kersh

Centers for Disease Control
Atlanta, Georgia, USA
PDF Slides


11:00 - 11:15       High HIV Incidence and HBV Vaccination Uptake

in a Preparatory Cohort Study Among Men who
have Sex with Men in Bangkok, Thailand, 2006-2010

Timothy Holtz

Thailand MOPH-Centers for Disease Control and Prevention Collaboration
Nonthaburi, Thailand
PDF Slides


11:15 - 11:30       HIV Incidence and Risk Factors for Acquisition in

HIV Discordant Couples in Masaka, Uganda: A
Prospective HIV Vaccine Trial Feasibility Study

Eugene Ruzagira

MRC/UVRI Uganda Research Unit on AIDS
Entebbe, Uganda
PDF Slides


11:30 - 11:45       Reduction of HIV Transmission Risk While

Prescribed Antiretroviral Therapy (ARVT):
Misclassification of ARVT Status as a
Methodological issue

Patrick Sullivan

Emory University
Atlanta, Georgia, USA
PDF Slides


11:45 - 12:00       Cost-per-HIV Infection Averted in Africa by

Couples' HIV testing vs Antiretroviral Treatment:
HIV Prevention in a 2010 Global Economy

Susan Allen

School of Medicine/Rwanda Zambia HIV Research Group
Atlanta, Georgia, USA
PDF Slides


12:00 - 12:30       Current Status of Evidence Based Prevention Strategies

Catherine Hankins

Joint United Nations Programme on HIV/AIDS
Geneva, Switzerland
PDF Slides



Oral Abstract Session 08: Innate & Mucosal Immunity
PDF Abstracts

10:30 - 10:45       Effect of Fc?-receptor Polymorphisms in Rhesus
Macaques on SIVmac251 Setpoint Viremia
Jorn Schmitz, Beth Israel Deaconess Medical Center
Boston, Massachusetts, USA

10:45 - 11:00       High Titers of Cross-Clade ADCC-Mediating
Antibodies are Detectable in Plasma Samples
Collected from Individuals with Broadly
Neutralizing Antibodies

Justin Pollara, Duke University Medical Center
Durham, North Carolina, USA
PDF Slides

11:00 - 11:15       The Role of HIV-1 peptide specificity in Modulating

KIR+ Natural Killer (NK) cell Function
Lena Fadda

Ragon Institute of MGH, MIT & Harvard
Charleston, Massachusetts, USA


11:15 - 11:30       A DNA Plasmid Prime and rAd5 Boost Vaccine

Regimen applied to the Tonsils Elicits Strong
Cellular and Humoral Immune Responses in
Rhesus Macaques

Ann Duerr

HIV Vaccine Trials Network
Seattle, Washington, USA
PDF Slides


11:30 - 11:45       Dissecting the Protective Mechanisms in

Cervicovaginal Tissues of SIVmac239 nef-
Vaccinated Macaques against Pathogenic SIV Challenge

Qingsheng Li

University of Minnesota
Shoreview, Minnesota, USA
PDF Slides


11:45 - 12:00       SIV Infection Results in Loss of IL-17-Producing

NK Cells in Mucosal Tissues, Which Contributes
to Damage to the Mucosal Barrier

Nichole Klatt, NIA Winner

NIH/NIAID
Bethesda, Maryland, USA


12:00 - 12:15       HIV-1 Elite Controllers resist HIV-1 Infection via

p21 (cip-1/waf-1)
Huabiao Chen, NIA Winner

Ragon Institute of MGH, MIT, and Harvard
Charlestown, Massachusetts, USA
PDF Slides


12:15 - 12:30       A Comparison of Systemic Innate Immune

Responses to the MRKAd5/HIV and MVA/HIV
Candidate HIV Vaccines

Erica Andersen-Nissen

Fred Hutchinson Cancer Research Center
Seattle, Washington, USA



Oral Abstract Session 09: B-Cell Immunology
PDF Abstracts

10:30 - 10:45       Early Plasma B Cell Responses to Transmitted

HIV-1 are Directed to Envelope gp41 and Originate
by the Activation of Mutated B Cell Clones

Hua-Xin (Larry) Liao

Duke University
Durham, North Carolina, USA


10:45 - 11:00       Nonpathogenic SIV infection of Sooty Mangabeys

is not Associated with High Levels of Autologous
Neutralizing Antibodies

Cynthia Derdeyn

Emory University
Atlanta, Georgia, USA
PDF Slides


11:00 - 11:15       Mechanism of Neutralization by Monoclonal

Antibody VRC01, a CD4 Binding Site Directed
Neutralizing Antibody with Extensive
Neutralization Breadth

Yuxing Li

NIH/NIAID
Bethesda, Maryland, USA


11:15 - 11:30       Epitope Specificities of Elite Neutralizing Sera

from HIV-1-Infected Individuals
Georgia Tomaras

Duke University Medical Center
Durham, North Carolina, USA


11:30 - 11:45       Mapping of Residues Critical for Neutralisation by

a Broadly Cross-neutralising Antibody Targeting a
Quaternary Epitope on the HIV-1 Envelope

Daniel Sheward

IIDMM, University of Cape Town
Cape Town, Western Cape, South Africa


11:45 - 12:00       Germline Variable Genes Code for Contact

Residues Maintained During Affinity Maturation of
Human anti-V3 Monoclonal Antibodies Encoded by VH5-51

Miroslaw K. Gorny

New York University School of Medicine
New York, New York, USA


12:00 - 12:15       Genetic Characteristics of HIV-1 Envelope

Associated with Broadly Cross-Reactive
Neutralizing Antibody Responses

Ruwayhida Thebus

Division of Virology - University of Cape Town
Cape Town, Western Cape, South Africa


12:15 - 12:30       Mapping Defects in IgM+ B Cell Repertoire in HIV-

Infected Individuals by 454-Pyrosequencing
Li Yin

University of Florida
Gainesville, Florida, USA



Oral Abstract Session 10: B Cell Vaccine Concepts
PDF Abstracts

13:30 - 13:45       Antigenicity and Immunogenicity of

Transmitted/Founder HIV Envelope Oligomers
Compared to Chronic HIV Envelopes

Chun-Yen (Jim) Tsao

Duke Human Vaccine Institute
Durham, North Carolina, USA


13:45 - 14:00       Engineered Immunogen Presenting an Epitope

Recognized by a Neutralizing mAb Elicits
Mammalian Serum that Recapitulate the mAb's Specificity

Timothy Cardozo

New York University School of Medicine
New York, New York, USA


14:00 - 14:15       Biophysical, Antigenic and Immunological

Analysis of HIV-1 Env Constructs Designed to
Focus the B Cell Response on Conserved Elements

Yu Feng

International AIDS Vaccine Initiative (IAVI)
San Diego, California, USA


14:15 - 14:30       Computationally Identified Mutations Suspected

to Cause gp120 Charge Inversion and gp41-
Mediated Allosteric Effects Impact IgG1b12 Susceptibility

David Montefiori

Duke University
Durham, North Carolina, USA


14:30 - 14:45       Map of Broad and Narrow Neutralization in the

V3 Loop Crown
David Almond

New York University School of Medicine
New York, New York, USA


14:45 - 15:00       High Through-put Functional Screening of

Activated B cells from 4 African Elite
Neutralizers Yields a Panel of Novel Broadly
Neutralizing Antibodies

Pascal Poignard

IAVI and The Scripps Research Institute
La Jolla, California, USA



Oral Abstract Session 11: Virology & Immunology of Transmission
PDF Abstracts

13:30 - 13:45       Identification of the First Cells Infected During

Vaginal Transmission in the Depo-Provera Rhesus
Macaque Model

Katharina Rothwangl

Northwestern University
Chicago, Illinois, USA
PDF Slides


13:45 - 14:00       Susceptibility of Epithelial Cells from the Human

Female Upper Reproductive Tract to Infection by
Transmitted/Founder HIV-1

Christina Ochsenbauer

University of Alabama at Birmingham
Birmingham, Alabama, USA
PDF Slides


14:00 - 14:15       HIV Env Antibodies Differentially Modulate Viral

Transport in Cervical Mucus
Gianguido Cianci

Northwestern University
Chicago, Illinois, USA
PDF Slides


14:15 - 14:30       Low Dose Mucosal SIV Infection Restricts Early

Replication Kinetics and Transmitted Virus
Variants in Rhesus Monkeys

Jinyan Liu

Harvard Medical School
Boston, Massachusetts, USA
PDF Slides


14:30 - 14:45       Exploring HIV Transmission in the Male Genital

Tract Using the Circumcised and Uncircumcised
Macaque Model

Minh Dinh

Northwestern University
Chicago, Illinois, USA
PDF Slides


14:45 - 15:00       Differences In Glycosylation Patterns but not

Neutralization Sensitivity of HIV-1 Env in Acute
and Chronic Infection From Heterosexual
Transmission

Ronald Swanstrom

UNC Chapel Hill
Chapel Hill, North Carolina, USA
PDF Slides



Roundtable Discussion
PDF Abstracts

13:30 - 13:50       Changing Landscapes - Integrating Emerging

Prevention Data into Clinical Trials
Ian McGowan

University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, USA
PDF Slides


13:50 - 14:10       Integrating HIV Prevention Interventions into HIV

Vaccine Trial Designs: Statistical Issues
Steve Self

Fred Hutchinson Cancer Research Center
Seattle, Washington, USA
PDF Slides


14:10 - 14:30       Ethical Frameworks and Standards of Prevention
in HIV Prevention Trials
Sean Philpott
The Bioethics Program of Union Graduate College and the Mount Sinai School of Medicine
Schenectady, New York, USA
PDF Slides

14:30 - 15:00       Panel Discussion
Ian McGowan

Sean Philpott

Steve Self

Mathew Rose
The National Coalition for LGBT Health
Washington, DC, USA


Symposium 04: Blocking HIV/SIV Acquisition
PDF Abstracts

16:00 - 16:25       Defining the Interaction of HIV with the Mucosal

Barriers to Gain Insights into the Mechanisms of
Sexual Transmission

Thomas Hope

Northwestern University
Chicago, Illinois, USA


16:25 - 16:50       Blocking Acquisition Across Mucosal Surfaces

Robin Shattock

St George's University of London
London, United Kingdom


16:50 - 17:15       Mucosal gp41-specific IgA: from Natural
Protection to Protective Vaccine Design
Morgane Bomsel
Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University
Paris, France

17:15 - 17:40       Immune and Genetic Correlates of Vaccine

Protection Against SIVsmE660 Mucosal Infection
in Rhesus Monkeys

Norman Letvin

Harvard Medical School
Boston, Massachusetts, USA


17:40 - 18:05       Preclinical Studies on DNA/MVA Vaccines; Co-

expressed GM-CSF, A Strong Adjuvant for
Blocking Transmission

Harriet Robinson

GeoVax, Inc.
Atlanta, Georgia, USA



Symposium 05: Linking Innate & Adaptive Immunity - the Role of Host Genetics
PDF Abstracts

16:00 - 16:25       Lessons on Antiviral Control from Evolution

Amalio Telenti

University of Lausanne
Lausanne, Vaud, Switzerland


16:25 - 16:50       Manipulating Memory CD8 T Cell Differentiation in
Prime-Boost Vaccination
John Harty
University of Iowa, Departments of Microbiology, Pathology and Interdisciplinary Program in Immunology
Iowa City, Iowa, USA

16:50 - 17:15       Novel Methods of Antiviral Control

David Brooks

University of California, Los Angeles
Los Angeles, California, USA


17:15 - 17:40       The Role of Immune Activation in Modulating Immunity

Jason Brenchley

Lab of Molecular Microbiology / NIAID / NIH
Bethesda, Maryland, USA


17:40 - 18:05       TRIM5 is an Innate Immune Receptor for the

Capsid of HIV-1
Jeremy Luban

University of Geneva
Geneva, Switzerland



Symposium 06: Recent Advances in B-cell and Protective Antibody Responses
PDF Abstracts

16:00 - 16:25       Few and Far Between: How HIV May Be Evading

Antibody Avidity and What We Can Do About It
Ron Diskin

California Institute of Technology
Pasadena, California, USA
PDF Slides


16:25 - 16:50       Isolation of a Novel anti-HIV gp41 Membrane

Proximal Region Neutralizing Antibody by
Antigen-specific Single B Cell Sorting
Lynn Morris

National Institute for Communicable Diseases
Johannesburg, Gauteng, South Africa


16:50 - 17:15       Pathways for Inducing Broad Neutralizing

Antibodies: Overcoming Anergy and Targeting
Germline B Cell Receptors for Generation of HIV-1
Protective Antibodies

Barton Haynes

Duke Human Vaccine Institute
Durham, North Carolina, USA


17:15 - 17:40       A Limited Number of Antibody Specificities

Mediate Broad and Potent Serum Neutralization in
Selected HIV-1 Infected Individuals

Laura Walker

The Scripps Research Institute
San Diego, California, USA
PDF Slides


17:40 - 18:05       Isolation and Characterization of Neutralizing

Monoclonal Antibodies Targeting the CD4 Binding Site
Xueling Wu

Vaccine Research Center, NIAID, NIH
Bethesda, Maryland, USA



Friday, 1 October, 2010

Symposium 07: Systems Biology in HIV Vaccine Research
PDF Abstracts

08:30 - 08:55       Integrating Systems Biology Approaches for

Vaccine Discovery
Michael Katze

University of Washington
Seattle, Washington, USA


08:55 - 09:20       Extracting Cell-Type-Specific Differences

from Complex Tissues
Shai Shen-Orr

Stanford University
Stanford, California, USA


09:20 - 09:45       Learning Immunology from Successful

Vaccines: Innate Immunity to Systems Vaccinology
Bali Pulendran

Emory University
Atlanta, Georgia, USA


09:45 - 10:10       Integrative Genomic Analysis of T cell

Immunity to HIV
W. Nicholas Haining

Dana-Farber Cancer Institute
Boston, Massachusetts, USA



Symposium 08: Bridging and Sustaining Community Partners in the Evolving Search for an AIDS Vaccine
PDF Abstracts

08:30 - 08:55       Balancing Discovery and Development: How

Do We Inform and Engage Communities in
the Constantly Evolving Scientific Universe?

Paula Frew

Emory University
Atlanta, Georgia, USA
PDF Slides


08:55 - 09:20       Enrollment and Beyond: Recruiting and
Retaining 16,000 Participants and What
Comes Next

Nusara Thaitawat
Department of Retrovirology, US Army Medical Component Armed Forces Research Institute of Medical Sciences
Bangkok, Thailand
PDF Slides

09:20 - 09:45       Adolescents: Still the Missing Cohort

Linda-Gail Bekker

Desmond Tutu HIV Foundation
Cape Town, South Africa
PDF Slides


09:45 - 10:10       Making GPP Come Alive: Experiences from
implementing Good Participatory Practice
Guidelines for Biomedical HIV Prevention Trials

Gabriela Calazans
Unidade de Pesquisa de Vacinas Anti-HIV - Centro de Referencia e Treinamento DST/AIDS - Sao Paulo HVTU
Sao Paulo, Brazil

Mitchell Warren
AVAC: Global Advocacy for HIV Prevention
New York, New York, USA
PDF Slides

Symposium 09: A Potential Role for Binding/ADCC Antibodies in Protection Against HIV Acquisition
PDF Abstracts

08:30 - 08:50       Modulation of IgG Activity by Differential Glycosylation
Falk Nimmerjahn
University of Erlangen-Nuernberg, Institute of Genetics, Department of Biology
Erlangen, Germany

08:50 - 09:10       The Role of Fcy Receptor Mediated Mechanisms in

Protection against HIV Mucosal Challenge
Ann Hessell

The Scripps Research Institute
La Jolla, California, USA


09:10 - 09:30       Mechanisms of Altered ADCC Inducing

Antibodies in Progressive HIV Infection
Galit Alter

Ragon Institute
Charleston, Massachusetts, USA


09:30 - 09:50       Antibody-Dependent Cell-Mediated Virus

Inhibition (ADCVI) Antibodies Elicited by
Vaccination

Donald Forthal

University of California, Irvine School of Medicine
Irvine, California, USA


09:50 - 10:10       Unraveling Mechanisms Underlying Protective NK
Cell Responses to HIV-1 Peptides: more than ADCC?
Caroline Tiemessen
AIDS Virus Research Unit, National Institute for Communicable Diseases
Johannesburg, Gauteng, South Africa


Plenary Session 03: Challenges Facing AIDS Vaccine Development
PDF Abstracts

10:40 - 11:10       Correlates of Immunity: RV144 - Lessons Learned
Nelson Michael
US Military HIV Research Program (MHRP) / Walter Reed Army Institute of Research
Rockville, Maryland, USA
PDF Slides

11:10 - 11:40       Systems Biology Approaches to HIV Vaccine Development
Rafick-Pierre Sekaly
Vaccine and Gene Therapy Institute Florida
Port Saint Lucie, Florida, USA and the Université de Montréal, Montreal, Canada
PDF Slides

11:40 - 12:10       The Need for More Efficient Efficacy Trials of HIV Vaccines

Lawrence Corey

Fred Hutchinson Cancer Research Center
Seattle, Washington, USA
PDF Slides


12:10 - 12:40       Using Partnerships in the Developing World to

Accelerate AIDS Vaccine Development
Seth Berkley

International AIDS Vaccine Initiative (IAVI)
New York, New York, USA
PDF Slides


12:40 - 13:10       Impact of Biomedical Prevention Approaches on

the Implementation of HIV Vaccine Efficacy Trials
Salim Abdool Karim

CAPRISA, University of KwaZulu-Natal
South Africa
PDF Slides



Closing Session

13:10 - 13:15       Closing Remarks
Eric Hunter, 2010 Conference Chair
Emory University, Atlanta, Georgia, USA

12:40 - 13:10       AIDS Vaccine 2011
Pratap Singhasivanon, 2011 Conference Chair
Mahidol University
Bangkok, Thailand